Final answer:
GLP-1 receptor agonists carry a black box warning for an increased risk of thyroid C-cell tumors, including a risk of medullary thyroid carcinoma.
Step-by-step explanation:
The black box warning for GLP-1 receptor agonists (GLP-1 RAs) is particularly concerned with the increased risk of thyroid C-cell tumors, including medullary thyroid carcinoma. This is due to observations from animal studies, though it is not definitively proven in humans.
GLP-1 receptor agonists are a class of medications used to treat type 2 diabetes by mimicking the incretin hormones, which increase insulin release and decrease glucagon secretion to lower blood sugar. Despite the potential anti-hyperglycemic benefits, patients prescribed these medications should be made aware of the increased risk of thyroid tumors indicated by the warning and monitored for any symptoms of thyroid cancer.